<DOC>
	<DOCNO>NCT00006367</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . PURPOSE : Phase II trial study effectiveness chemotherapy follow peripheral stem cell transplantation treat patient myelofibrosis .</brief_summary>
	<brief_title>Chemotherapy Followed Peripheral Stem Cell Transplantation Treating Patients With Myelofibrosis</brief_title>
	<detailed_description>OBJECTIVES : I . Determine ability myeloablative chemotherapy follow peripheral blood stem cell ( PBSC ) transplantation restore effective marrow hematopoieses patient advanced idiopathic myelofibrosis myelofibrosis secondary myeloproliferative disorder . II . Determine ability regimen palliate symptom prolong survival patient . III . Determine evidence clonal hematopoieses PBSC mobilization , PBSC product , transplantation patient . IV . Correlate property peripheral blood mobilization PBSC product engraftment patient . V. Correlate marker angiogenesis clinical parameter patient . OUTLINE : Patients evidence leukemic progression receive cytoreduction therapy consist idarubicin IV day 1-3 cytarabine IV continuously day 1-7 follow filgrastim ( G-CSF ) subcutaneously ( SC ) daily blood count recover leukapheresis complete . Patients undergo leukapheresis begin blood count recover continue target number cell collect . Patients evidence leukemic progression receive filgrastim SC daily leukapheresis complete . Patients undergo leukapheresis begin day 4 continue target number cell collect . Patients receive myeloablative therapy consist oral busulfan every six hour day -5 -2 . Patients leukemic progression begin myeloablative therapy least 28 day completion chemotherapy . Patients receive autologous peripheral blood stem cell IV day 0 . Patients follow 1 month , 3 month , 1 year , annually thereafter . PROJECTED ACCRUAL : A total 10-44 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis idiopathic myelofibrosis myeloproliferative disorder myelofibrosis Evidence advance disease hematologic abnormality due severe fibrosis 1 follow poor prognostic factor : Hemoglobin le 10 g/dL Platelet count le 100,000/mm3 WBC less 4,000/mm3 Symptomatic splenomegaly Constitutional symptom inadequately control low dose chemotherapy Abnormal karyotype Patients without evidence advance disease undergo PBSC harvest transplantation delay evidence disease progression Leukemia progression ( great 15 % peripheral blood blast ) allow history chronic myeloproliferative disorder least 6 month duration well document Ineligible refusal allogeneic transplantation No cause myelofibrosis myeloproliferative disorder , follow : Metastatic carcinoma Lymphoma Hairy cell leukemia Myelodysplastic syndrome De novo acute leukemia Collagen vascular disorder Granulomatous infection PATIENT CHARACTERISTICS : Age : 75 Performance status : Not specify Life expectancy : Not specify Hematopoietic : See Disease Characteristics WBC great 30,000/mm3 ( may reduce less 30,000/mm3 use hydroxyurea induction chemotherapy ) Hepatic : Bilirubin great 2 time upper limit normal ( ULN ) * Transaminases great 2 time ULN* * Unless due extramedullary hematopoiesis liver Renal : Creatinine great 2 time normal OR Creatinine clearance least 50 % Cardiovascular : No prior active congestive heart failure* LVEF least 50 % * *If receiving study cytoreductive therapy Pulmonary : Total lung capacity least 50 % predict OR Corrected DLCO least 50 % predict Other : No active infection No poorly control seizure disorder Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Chemotherapy : See Disease Characteristics At least 7 day since prior hydroxyurea Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>polycythemia vera</keyword>
	<keyword>chronic idiopathic myelofibrosis</keyword>
	<keyword>essential thrombocythemia</keyword>
</DOC>